* MAGNISENSE *
2003 - IDF
Rosny-sous-Bois (near Paris)
www.magnisense.com Discovery, Diagnostics
Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek, MIAstrip, MIAflo
Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods)
Clients: Diagnostic industry
info@magnisense.com
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little]
Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.]
Fin.Dir.-CFO:
RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.]
BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata]
Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€)
Note : legal foundation, February 20. 2007 (not 2003, as per company) | Turnover (M€) : 0.2 (2007)
Total funding (M€) : 7.0
Last funding (M€) : 1.0
Focus : Point of Care Testing
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .08 | Round-financing : 1 M€, by existing shareholders, to support MIAtek technology platform development | RFIN | [8 years] |
| 2011 .02 | Legal move with Magnisense France as a dissolved company, replaced by Magnisense SE for R&D, and headquarters in Luxemburg | ORGF | [7 years] |
| 2008 .10 | Clinical trial positive, to view and characterize tissue lining the common bile duct at a microscopic level in real time with Cellvizio device, the world's smallest microscope | CLIN | [5 years] |
| 2008 .04 | Launch of MIAplex, a multiparametric magnetic technology | MKTG | [4 years] |
| 2008 .03 | Company expansion with new laboratories facility in Dardilly (near Lyon) | ORGC | [4 years] |
| 2007 .04 | Patent : filed for the invention of a new multiparametric magnetic immunoassay | LEGAL | [3 years] |
| 2007 .02 | Partnering development agreement with Indicia Biotechnology for joint testing platform of magnetic marker-based in vitro diagnostics | R&D | [3 years] |
| 2006 .12 | Nomination : Luc Lenglet, as CEO | ORGN | [3 years] |
| 2006 .06 | 2nd round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors | RFINB | [3 years] |
| 2006 .03 | Patent : filed to protect special features of adapted lateral flow membrane cartridges | LEGAL | [2 years] |
| 2003 .07 | Patent : filed to protect a special embodiment of the technology | LEGAL | [0 year] |
| 2003 .06 | 1st round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors | RFINA | [0 year] |
| 2003 .05 | Company founded by Baring Vostok Capital Partners and private investors, from technical development carried out jointly with the Russian Academy of Sciences in Moscow and Bertin technologies in France for engineering | ORGF | [0 year] | Actualisation / Updating: 28-Sep-2011 |
|
